Trial Profile

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV 711 (Primary) ; Budigalimab (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors AbbVie

16 Dec 2025 Planned End Date changed from 1 Apr 2029 to 1 Oct 2030.
08 Dec 2025 Planned End Date changed from 1 Oct 2030 to 1 Apr 2029.
08 Dec 2025 Planned primary completion date changed from 1 Oct 2030 to 1 Apr 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com